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for techniPurpose: To develop a positron emission tomography (PET)-based response predictionmodel to differentiate path-
ological responders from nonresponders. The predictive strength of the model was validated in a second patient
group, treated and imaged identical to the patients on which the predictive model was based.
Methods andMaterials: Fifty-one rectal cancer patients were prospectively included in this study. All patients un-
derwent fluorodeoxyglucose (FDG) PET-computed tomography (CT) imaging both before the start of chemoradio-
therapy (CRT) and after 2 weeks of treatment. Preoperative treatment with CRT was followed by a total
mesorectal excision. From the resected specimen, the tumor regression grade (TRG) was scored according to
the Mandard criteria. From one patient group (n = 30), the metabolic treatment response was correlated with
the pathological treatment response, resulting in a receiver operating characteristic (ROC) curve based cutoff
value for the reduction of maximum standardized uptake value (SUVmax) within the tumor to differentiate path-
ological responders (TRG 1–2) from nonresponders (TRG 3–5). The applicability of the selected cutoff value for
new patients was validated in a second patient group (n = 21).
Results: When correlating the metabolic and pathological treatment response for the first patient group using
ROC curve analysis (area under the curve = 0.98), a cutoff value of 48% SUVmax reduction was selected to differ-
entiate pathological responders from nonresponders (specificity of 100%, sensitivity of 64%). Applying this cutoff
value to the second patient group resulted in a specificity and sensitivity of, respectively, 93% and 83%, with only
one of the pathological nonresponders being false positively predicted as pathological responding.
Conclusions: For rectal cancer, an accurate PET-based prediction of the pathological treatment response is fea-
sible already after 2 weeks of CRT. The presented predictive model could be used to select patients to be
considered for less invasive surgical interventions or even a ‘‘wait and see’’ policy. Also, based on the predicted
response, early modifications of the treatment protocol are possible, which might result in an improved clinical
outcome.  2012 Elsevier Inc.
Locally advanced rectal cancer, Chemoradiotherapy, Sequential PET-CT imaging, Pathological response predic-
tion, TRG.INTRODUCTION
Over the past several years, the reduction of the metabolic
activity of rectal tumors during preoperative treatment,
assessed with repeated positron emission tomography
(PET)-computed tomography (CT) imaging, has been shown
to accurately predict the pathological treatment response (1–
14). Most of the published studies about PET-based treatment
response predictions determined a (receiver operating charac-
teristic [ROC] curve based) cutoff value, percent reduction oft requests to: Marco H.M. Janssen, M.Sc., MAASTRO
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871the mean, or maximum standardized uptake value (SUVmax)
within the tumor after finishing preoperative treatment, to dif-
ferentiate pathological responders from nonresponders.
However, also early metabolic treatment responses within
the tumor, as early as 2 weeks after the start of preoperative
treatment, were presented as a strong predictor of the patho-
logical treatment response (9, 10, 12). Two studies even
presented early PET-based response predictions as being
more accurate when compared to response predictions basedport from the Netherlands Organization for Health Research and
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of the pathological treatment response early during
preoperative treatment is more attractive for clinical
practice, because this enables individualized treatment
schemes in the near future, possibly resulting in an
improved tumor control or modified surgical approaches
like less invasive or delayed surgery in combination with an
intensive imaging follow-up.
The main objective of a PET-based predictive model is the
actual prediction of the pathological treatment response for
patients not included in the patient group on which themodel
is based. However, so far, none of the presented PET-based
response predictive models was yet validated with a second-
ary patient group. Because for further development and clin-
ical usefulness of PET-based response predictive models
a proper validation with a secondary group is required, this
study was undertaken to develop a PET-based prediction
model to differentiate pathological responders from nonre-
sponders. The predictive strength of the presented predictive
model was validated in a second patient group, treated, and
imaged identical to the patients on which the predictive
model was based.METHODS AND MATERIALS
Patient Characteristics
Fifty-one patients diagnosed with locally advanced rectal cancer
were included in this study, from which the clinical TN staging was
evaluated on a pretreatment magnetic resonance scan (Table 1). All
patients were preoperatively treated with radiotherapy (28 fractionsTable 1. Overview of the clinical staging (cTNM), the tumor regressi
weeks of preoperative c
Patient no. cTNM TRG RI SUVmax (%)
1 T2N1M0 1 51.9
2 T3N2M0 3 41.7
3 T3N2M0 2 69.4
4 T4N2M0 2 38.9
5 T3N1M0 2 64.8
6 T3N2M0 3 31.5
7 T3N1M0 3 11.8
8 T3N2M0 3 47.6
9 T3N2M0 4 14.4
10 T3N1M0 1 70.4
11 T3N2M0 4 28.8
12 T3N1M0 3 40.8
13 T3N0M0 3 4.1
14 T3N2M0 3 35.9
15 T3N2M0 3 33.6
16 T3N2M0 4 28.6
17 T3N2M0 1 54.6
18 T3N2M0 2 45.5
19 T3N0M0 4 5.2
20 T3N2M1 3 8.2
21 T4N1M0 4 15.7
22 T3N0M0 2 48.6
23 T3N0M0 1 68.4
24 T3N2M0 2 45.6
25 T3N2M0 2 46.7
26 T3N1M0 4 7.1of 1.8 Gy, 5 fractions/week) and concomitant chemotherapy (capeci-
tabine 825 mg/m2 twice daily, 7 days per week), followed by a total
mesorectal excision approximately 3 months after the start of preop-
erative treatment (Fig. 1). Radiotherapy treatment was delivered by
four beams, anteroposterior, posteroanterior, and left and right lateral,
each with an energy of 10MV. For each patient, a three-dimensional
(3D) conformal plan was made according to the International Com-
mission on Radiation Units and Measurements specifications. As
a part of the study, all patients underwent fluorodeoxyglucose
(FDG) PET-CT imaging both before the start of CRT and at the end
of the second week of treatment (Fig. 1). According to the Dutch
law, the Medical Ethics Committee approved the trial. All patients
gave written informed consent before entering the study.PET-CT imaging and processing
All PET-CT scans were performed using a dedicated Siemens Bi-
ograph 40 TruePoint PET-CT simulator (Siemens Medical, Erlan-
gen, Germany) with an axial field of view of 16.2 cm, slice
thickness of 3 mm, and a pixel spacing of 5.3456 mm in both
directions. The scanner is equipped with ultrafast detector
electronics (Pico3D) and has a spatial resolution of approximately
6-mm full-width-at-half-maximum. PET imaging was performed in
3D, requiring a proper scatter correction. CT-based attenuation and
decay correction was performed. PET images were reconstructed
from the acquired list-mode data using Fourier-rebinning and
ordered-subset-expectation-maximization-reconstruction (OSEM
2D) with four iterations and eight subsets. After a fasting period
of at least 6 h, FDG was injected intravenously, with the activity
normalized for the weight of the patient (weight [kg]*4 + 20)
[MBq]). After an uptake period of 60 min, PET acquisition was
started with the patient positioned equal to the radiotherapy treat-
ment position using a movable laser alignment system.on grade (TRG), and the response index (RI) of SUVmax after 2
hemoradiotherapy
Patient no. cTNM TRG RI SUVmax (%)
1 T4N1M0 3 47.6
2 T3N1M0 3 9.2
3 T3N0M0 1 62.5
4 T4N1M0 4 16.9
5 T3N2M0 1 69.1
6 T3N0M0 4 19.9
7 T3N2M0 4 2.9
8 T2N1M0 2 55.9
9 T3N2M0 4 10.6
10 T3N1M0 3 54.4
11 T3N1M0 1 45.3
12 T3N2M0 3 40.0
13 T3N1M0 4 15.0
14 T3N2M0 4 45.1
15 T2N0M0 3 1.2
16 T3N2M0 2 63.2
17 T3N0M0 3 37.7
18 T3N0M0 3 44.0
19 T3N1M0 1 53.1
20 T4N0M0 3 40.3
Fig. 1. Study scheme for the assessment of early metabolic response during pre-operative treatment with chemoradiother-
apy (CRT). All included patients underwent fluorodeoxyglucose (FDG) positron emission tomography (PET) computed
tomography (CT) imaging at two time points: prior to the start of treatment and after two weeks of treatment.
PET-based prediction and validation of pathological treatment response d M. H. M. JANSSEN et al. 873Additionally, all PET data were normalized for the blood glucose
level measured shortly before FDG administration (15).
PET analysis
For each PET scan, the tumor was automatically delineated using
SUV thresholding with the threshold (percentage of SUVmax within
the tumor) depending on the tumor-to-background signal ratio with
the gluteus muscle selected as relevant background (16, 17).
Dedicated software (TrueD VC60, Siemens Medical, Erlangen,
Germany) was used to calculate the maximum FDG uptake
(SUVmax) within the tumor. Subsequently, a response index,
indicating the percentage reduction relative to the pre-treatmentmea-
sured value, was calculated.
Pathological tumor response
For each tumor, the pathological treatment response was evalu-
ated by determination of the tumor regression grade (TRG) as
proposed by Mandard (18). All tumors were retrospectively clas-
sified by an experienced pathologist (R.R.), who was blinded for
the PET data, as follows: TRG1, complete tumor response;
TRG2, residual cancer cells scattered through fibrosis; TRG3,
an increased number of residual cancer cells, with predominant fi-
brosis; TRG4, residual cancer outgrowing fibrosis; TRG5, no
regressive changes within the tumor. Based on the TRGs, the
patients were grouped into pathological responders (TRG1, 2)
and nonresponders (TRG 3–5).
Response prediction and validation
For 30 of the included patients, the metabolic and pathological
treatment responses were correlated using ROC curve analysis.
From the ROC curve, a cutoff value for the percent reduction of
SUVmax within the tumor after 2 weeks of chemoradiotherapy
(CRT) treatment was selected to differentiate pathological
responders from non-responders. When selecting this cutoff value,
a high specificity was preferred over a high sensitivity to avoid
pathological nonresponders from being false positively predicted
as pathological responders, resulting in possible undertreatment
of pathological nonresponding patients. Next, the applicability of
the selected cutoff value was validated for new patients (n = 21),
imaged and treated under identical conditions as the patients on
which the predictive model was based.
Statistical Analysis
Statistical analyses were performed using SPSS (version 15.0;
SPSS Inc., Chicago, IL).
Comparisons of related measurements were performed using
a Wilcoxon signed-rank test and ROC analysis was performed to
evaluate the optimal cutoff value of SUVmax reduction to differen-
tiate pathological responders from nonresponders.RESULTS
Peritumoral inflammatory responses
From the first patient group (n = 30), 4 patients pre-
sented with a peritumoral inflammatory response, visually
observed from the PET scan performed at the end of the
second week of treatment. Also for the second patient
group (n = 21), used for validation of the predictive
model, 1 patient presented with a peritumoral inflamma-
tory response. Because inflammatory cells are known to
avidly consume glucose, all patients with a peritumoral
inflammatory response were excluded from further analy-
sis to prevent an underestimation of the metabolic treat-
ment response of the tumor. When delineating the tumor
using automatic SUV thresholding, an increase of the
PET-positive tissue volume was found after 2 weeks of
CRT treatment for the previously mentioned patients
(Fig. 2). The increase of the PET-positive tissue volume
is a clear indication of a peritumoral inflammatory re-
sponse, since an increase of the volume of the malignancy
is not to be expected during preoperative CRT treatment.
Also, for these patients, a more diffuse FDG uptake was
observed after 2 weeks of treatment with a decreased
tumor-to-background signal ratio resulting in a less clear
PET-based distinction between malignant and nonmalig-
nant tissue (Fig. 2). All visually observed peritumoral in-
flammatory responses after 2 weeks of treatment were
confirmed after pathological examination of the resected
specimen.Response prediction
For the first patient group, an average reduction of SUV-
max within the tumor of 33.6  25.8% (p < 0.001) was ob-
served after 2 weeks of CRT (Fig. 3, Table 1). The
SUVmax reduction within the tumor was correlated with
the pathological response by ROC curve analysis, resulting
in an area under the curve of 0.98 (Table 2). From the result-
ing ROC curve, a cutoff value of 48% SUVmax reduction was
selected to differentiate pathological responders from nonre-
sponders, resulting in a specificity of 100% to prevent path-
ological nonresponders from being false positively predicted
as pathological responder (Fig. 4). However, for this cutoff
value, a sensitivity of 64% was found, with 4 pathological
responding patients to be false negatively predicted as path-
ological nonresponding (Fig. 4).
Fig. 2. Fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) images at both
PET-CT imaging time points for respectively a representative patient (A) and a patient presenting with a pathological re-
ported peritumoral inflammatory response (B).
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Also for the second patient group, a significant reduction
of SUVmax within the tumor (32.3  27.0%, p = 0.001) was
found after 2 weeks of CRT (Fig. 3, Table 1). When applyingFig. 3. Boxplots of maximum standardized uptake value (SUVmax)
within the tumor at both positron emission tomography (PET) com-
puted tomography (CT) time points for both patient groups, with
the dark and light gray boxes presenting, respectively, the pretreat-
ment SUVmax within the tumor and the SUVmax after 2 weeks of
chemoradiotherapy.the ROC curve based cutoff value of 48% to differentiate
pathological responders from nonresponders, a specificity
and sensitivity of, respectively, 93% and 83% was found,
with only one of the pathological nonresponding patients
(TRG3) being predicted false positively as pathological re-
sponding, whereas one pathological responder (TRG1)
was predicted false negatively as being a pathological non-
responder (Fig. 4).DISCUSSION
Response predictive models based on changes of the
metabolic activity of the tumor, assessed with repeated
FDG-PET-CT imaging, were presented to result in accurate
predictions of the pathological treatment response (1–14).
However, proper validation of published PET-based
response predictive models has not yet been performed.
This is the first study performing a validation of a PET-
based response prediction model using a SUV cutoff value
to differentiate pathological responders from nonresponders.
Validation of such response predictive models is required to
ensure whether the presented model is applicable on patients
who are not included in the patient group on which the model
is based. When using a PET-based response prediction
model for the differentiation of pathological responders
Table 2. Overview of average metabolic response (RI
SUVmax) as assessed with fluorodeoxyglucose (FDG)
positron emission tomography (PET) imaging, relative to the
tumor regression grade (TRG)
RI SUVmax
TRG 1 59.4  9.4%; range, 45.370.4%
TRG 2 53.2  10.5%; range, 38.969.4%
TRG 3 26.7  22.9%; range, 11.854.4%
TRG 4 13.0  20.4%; range, 19.945.1%
TRG 1–2 56.1  10.2%; range, 38.970.4%
TRG 3–5 20.5  22.5%; range, 19.954.4%
PET-based prediction and validation of pathological treatment response d M. H. M. JANSSEN et al. 875and nonresponders, the cutoff value (percent reduction of the
FDG uptake within the tumor) used to differentiate
responders from nonresponders should be chosen in such
a way that as less nonresponding patients as possible are pre-
dicted false positively as pathological responding (12). This,
to avoid undertreatment of false positively predicted patho-
logical nonresponders when performing modifications of the
treatment protocol based on the predicted treatment
response. The selected ROC curve based cutoff value of
48% SUVmax reduction at the end of the second week of pre-
operative CRT (sensitivity 64%, specificity 100%) was
applied on a second patient group, resulting in a sensitivity
and specificity of respectively 83% and 93%, with one path-
ological nonresponder being predicted false positively as
pathological responding. From these results, it was con-
cluded that a PET-based predictive model using a cutoff
value (percent reduction of SUVmax within the tumor) can
be used to accurately predict the pathological treatment re-
sponse for patients not included in the patient group on
which the predictive model is based.
For this study, we defined patients with a TRG of 1 or 2
according to the Mandard criteria as being pathological
responders and patients with a TRG 3–5 as pathological non-
responders. Earlier published literature proved patients with
TRG1–2 to have a better prognosis compared to patients
with TRG3–5 (19, 20). Patients presenting with a TRG1 or
2 were proven to have less chance on local failure,Fig. 4. Response indices (RI) of maximum standardized uptak
diotherapy relative to the tumor regression grade (TRG) for bot
gray horizontal line indicates the receiver operating characteris
the differentiation of pathological responders from nonrespondwhereas they have an improved chance on metastasis- and
disease-free survival as well as overall survival (20). Also,
an extended time interval between preoperative CRT
treatment and surgery has been presented to result in more
pronounced tumor regression and downstaging, whereas
a shorter time interval may interrupt ongoing of tumor necro-
sis (21–23).We believe that a PET-based response predictive
model as presented in this manuscript could in the near
future be helpful to identify those TRG1–2 patients to
improve the tumor response by including these patients in
a boost trial and/or apply an extended time interval between
RT and surgery.
For some of the patients included in this study, a peritu-
moral inflammatory response was visually observed from
the PET images acquired after the second week of CRT.
As inflammatory cells are known to avidly consume glucose
(analogs), peritumoral inflammatory responses can lead to
an underestimation of the metabolic response of the tumor,
ultimately resulting in false-negative predictions of patho-
logical responders (10, 12, 24). Patients presenting with
a (visually observed) peritumoral inflammatory response
should not be included in the patient group on which
a PET-based response predictive model is based and such
PET-based response predictive model should not be applied
for patient with a peritumoral inflammatory response.
Importantly, when predicting the pathological treatment
response based on sequential PET data, standardization of
the used PET imaging protocol concerning the PET image
reconstruction algorithm, injected FDG activities and uptake
periods, SUV calculation method, blood glucose level mea-
surements and correction of the PET data for the blood glu-
cose level is required (11, 16, 25–28).
In conclusion, this is the first validation of a PET-based
model for the prediction of the pathological treatment
response. The presented results prove that an accurate pre-
diction of the pathological treatment response based on the
reduction of SUVmax is possible already after 2 weeks of
CRT treatment for patients treated and imaged identical to
the patients on which the response predictive model is based.e value (SUVmax) after 2 weeks of preoperative chemora-
h the prediction (left) and validation (right) database. The
tic curve based cutoff value of 48% SUVmax reduction for
ers.
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